India’s tissue-engineered skin substitutes market is witnessing growth as demand for advanced wound healing products increases to address chronic and complex wounds, burns, and ulcer care. Against this backdrop, the Indian market is projected to expand at a compound annual growth rate (CAGR) of around 10% through 2036, according to GlobalData, a leading intelligence and productivity platform.

GlobalData’s report, “Tissue Engineered Skin Substitutes Market Size by Segments, Share, Regulatory, Reimbursement, Interventions and Forecast to 2036,” reveals that India accounted for nearly 3% of the Asia-Pacific (APAC) tissue engineered skin substitutes market in 2025.

Aakansha Pankaj, Medical Devices Analyst at GlobalData, comments: “The Indian tissue-engineered skin substitutes market is gaining traction as clinicians place greater emphasis on products that promote faster healing, reduce scarring and improve clinical outcomes. Innovations that integrate seamlessly into the existing wound care protocols and demonstrate clear clinical benefit are likely to witness higher uptake over the forecast period.”

Amid an evolving medical technology landscape, Indian biotech innovator Alicorn Medical unveiled CholeDerm, a domestically engineered, extracellular matrix (ECM)-based Class D wound-healing medical device, in January 2026. Introduced at the Sree Chitra Tirunal Institute for Medical Sciences and Technology, it is engineered to enhance the body’s natural wound-healing processes. It signals a shift toward modern wound therapies that reduce complications, speed recovery, and lower overall treatment costs.

Pankaj concludes: “With strong growth projected for the Indian tissue-engineered skin substitutes market, manufacturers which can address ease of use, regulatory compliance and demonstrable clinical effectiveness will be well-positioned to capitalize on the expanding demand. Local innovations such as CholeDerm further bolster market confidence, creating opportunities for both domestic and global players.”